𝔖 Bobbio Scriptorium
✦   LIBER   ✦

“Pure” striatonigral degeneration and Parkinson's disease: A comparative clinical study

✍ Scribed by Dr. Neziha Gouider-Khouja; Marie Vidailhet; Anne-Marie Bonnet; Jacques Pichon; Yves Agid

Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
636 KB
Volume
10
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Striatonigral degeneration (SND) is difficult to diagnose in vivo. The purpose of this study was to detect the best indicators for an early and reliable diagnosis of the disease. Eighteen patients clinically diagnosed as having SND were selected with rigorous inclusion criteria and compared to 18 patients with Parkinson's disease (PD) matched for age and disease duration. Apart from dysautonomia, the principal discriminant clinical features that distinguished SND from PD were the early appearance of the following symptoms and signs: (a) severe and atypical progressive parkinsonism characterized by bilateral bradykinesia and rigidity, slowness of gait, postural instability, and falls, and poor or absent response to adequate levodopa treatment; (b) increased tendon reflexes associated or not with frank pyramidal signs, severe dysarthria, and less consistently, dysphagia, stridor, antecollis, and stimulussensitive myoclonus, which, when present, are highly suggestive of the disease.

📜 SIMILAR VOLUMES

Urinary disturbances in striatonigral de
Urinary disturbances in striatonigral degeneration and parkinson's disease: Clinical and urodynamic aspects
✍ Dr. A. M. Bonnet; J. Pichon; M. Vidailhet; N. Gouider-Khouja; G. Robain; M. Perr 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 445 KB

## Abstract Although urinary disturbances are more frequent in multiple system atrophy (MSA) than in Parkinson's disease (PD), the striatonigral degeneration (SND) type of MSA is difficult to distinguish from PD, especially when the latter is associated with orthostatic hypotension or urinary sympt

A clinical and genetic study of familial
A clinical and genetic study of familial Parkinson's disease
✍ Dr. D. M. Maraganore; A. E. Harding; C. D. Marsden 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 591 KB

The clinical features of familial Parkinson's disease (PD) were investigated by examining the families of 20 British probands who were selected on the basis of having clinically typical PD and at least one affected relative. Forty-nine secondary cases were identified. These subjects were clinically

A comparative study of physical performa
A comparative study of physical performance measures in Parkinson's disease
✍ Haruko Tanji; Ann L. Gruber-Baldini; Karen E. Anderson; Ingrid Pretzer-Aboff; St 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 223 KB

## Abstract The objective of this study is to compare physical performance measures for their ability to discriminate between levels of disability and disease severity in Parkinson's disease (PD). Disability in PD is commonly assessed by patient self‐report, which may be limited by patient insight.

Progression of dopaminergic degeneration
Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β-CIT SPECT study
✍ Walter Pirker; Schiva Djamshidian; Susanne Asenbaum; Willibald Gerschlager; Gott 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 1 views

## Abstract Atypical parkinsonian syndromes (APS) such as multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration are characterized by poor response to antiparkinsonian medication and rapid clinical deterioration. We used SPECT and [^123^I]β‐CIT as a label of dopamine

Rate of clinical progression in Parkinso
Rate of clinical progression in Parkinson's disease. A prospective study
✍ Anette Schrag; Richard Dodel; Annika Spottke; Bernhard Bornschein; Uwe Siebert; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 1 views

## Abstract Few prospective data on the clinical progression of Parkinson's disease (PD) in patient groups outside treatment trials in selected patients are available, and controversy exists on the rate of clinical disease progression with advancing disease. In this study, we investigated the rate